Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL515359 | 1.00 | MGLL (0.33) | MGLLCTSLCTSBCTSSCTSK | |
| SCHEMBL14084740 | 0.94 | MGLL (0.40) | MGLL | |
| SCHEMBL2457046 | 0.94 | MGLL (0.40) | MGLL | |
| Hydrochloric Acid SCHEMBL17260829 | 0.94 | MGLL (0.31) | MGLL | |
| SCHEMBL3658220 | 0.94 | MGLL (0.40) | MGLL | |
| SCHEMBL726729 | 0.94 | MGLL (0.40) | MGLL | |
| SCHEMBL6926105 | 0.94 | MGLL (0.40) | MGLL | |
| SCHEMBL513824 | 0.94 | — | — | |
| Bromide SCHEMBL15740961 | 0.94 | MGLL (0.31) | MGLL | |
| SCHEMBL42220 | 0.94 | MGLL (0.40) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 654 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4511855-A1 | HALOGENATED COMPOUNDS FOR ENERGY STORAGE DEVICE FORMULATIONS | Maxwell Technologies Korea Co., Ltd. (KR) | 2025-02-26 | — | — | EP | claimed |
| CN-118522956-A | Mixed quaternary ammonium salt electrolyte and double-carbon battery | 中国科学院长春应用化学研究所 | 2024-08-20 | — | — | CN | claimed |
| WO-2024050635-A1 | SPIRO-BASED IONIC LIQUID ELECTROLYTE FOR LOW TEMPERATURE SUPERCAPACITORS AND METHODS OF FABRICATING SAME | 10644137 CANADA INC. (CA) | 2024-03-14 | — | — | WO | claimed |
| CN-117229263-A | Compound for inhibiting or degrading Bcl6 and application of compound in medicine | 四川海思科制药有限公司 | 2023-12-15 | — | — | CN | claimed |
| CN-117050058-A | Fused heterocyclic compound, composition thereof and pharmaceutical application thereof | 四川海思科制药有限公司 | 2023-11-14 | — | — | CN | claimed |
| CN-116969921-A | Compound for inhibiting or degrading HPK1 kinase and application thereof in medicine | 四川海思科制药有限公司 | 2023-10-31 | — | — | CN | claimed |
| WO-2023205034-A1 | HALOGENATED COMPOUNDS FOR ENERGY STORAGE DEVICE FORMULATIONS | MAXWELL TECHNOLOGIES KOREA CO., LTD. (KR) | 2023-10-26 | — | — | WO | claimed |
| CN-116916724-A | Ion liquid heat management method of perovskite solar cell and application | 桂林电子科技大学 | 2023-10-20 | — | — | CN | claimed |
| CN-114031974-A | Ink for ink jet printing and electroluminescent device | 广东聚华印刷显示技术有限公司 | 2022-02-11 | — | — | CN | claimed |
| CN-110498904-A | Expediting setting type epoxy systems | EVONIK DEGUSSA GMBH | 2019-11-26 | — | — | CN | claimed |
| EP-1994022-A2 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2008-11-26 | — | — | EP | claimed |
| US-20080009637-A1 | Preparation of N-protected-3-pyrrolidine-lactam substituted phosphonium salts | BASILEA PHARMACEUTICA AG | 2008-01-10 | — | — | US | claimed |
| WO-2007108936-A2 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2007-09-27 | — | — | WO | claimed |
| EP-1311518-B1 | PREPARATION OF N-PROTECTED-3-PYRROLIDINE-LACTAM SUBSTITUTED PHOSPHONIUM SALTS | BASILEA PHARMACEUTICA AG (CH) | 2005-11-02 | — | — | EP | claimed |
| CN-1212327-C | Preparation of N-protected-3-pyrrolidine-lactam substituted phosphonium salts | BASILEA PHARMACEUTICA AG (CH) | 2005-07-27 | — | — | CN | claimed |
| CN-1451012-A | Preparation of N-protected-3-pyrrolidine-lactam substituted phosphonium salts | BASILEA PHARMACEUTICA AG (CH) | 2003-10-22 | — | — | CN | claimed |
| US-20030195364-A1 | Preparation of n-protected-3-pyrrolidine-lactam substituted phosphonium salts | BASILEA PHARMACEUTICA AG (CH) | 2003-10-16 | — | — | US | claimed |
| EP-1311518-A1 | PREPARATION OF N-PROTECTED-3-PYRROLIDINE-LACTAM SUBSTITUTED PHOSPHONIUM SALTS | Basilea Pharmaceutica AG (CH) | 2003-05-21 | — | — | EP | claimed |
| WO-2002014332-A1 | PREPARATION OF N-PROTECTED-3-PYRROLIDINE-LACTAM SUBSTITUTED PHOSPHONIUM SALTS | BASILEA PHARMACEUTICA AG (CH) | 2002-02-21 | — | — | WO | claimed |
| US-4058390-A | Amine salts of phenyl-4-hydroxypyridazines and the preparation and herbicidal compositions thereof | CHEMIE LINZ AKTIENGESELLSCHAFT (OE) | 1977-11-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009637-A1 | Preparation of N-protected-3-pyrrolidine-lactam substituted phosphonium salts | PNKP, PNISR, CLK3 | MGLL 3678/4885CTSL 1292/4885CTSB 3361/4885 |
| US-20030195364-A1 | Preparation of n-protected-3-pyrrolidine-lactam substituted phosphonium salts | PNKP, PHOSPHO1, PTMS | MGLL 3733/4885CTSL 1271/4885CTSB 3339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.